We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BioTek

BioTek Instruments, Inc., designs, manufactures, and distributes life science instrumentation. Its product line inclu... read more Featured Products: More products

Download Mobile App




Blood Analyses Predict Delirium Risk In Older Surgical Patients

By LabMedica International staff writers
Posted on 26 May 2016
Print article
Image: The Synergy multimode microplate reader ((Photo courtesy of BioTek Instruments).
Image: The Synergy multimode microplate reader ((Photo courtesy of BioTek Instruments).
Delirium, or sudden severe confusion due to rapid changes in brain function that can occur with physical or mental illness, affects 15% to 53% of older surgical patients and has been linked with longer hospital stays, greater postoperative complications, and higher rates of discharge to nursing homes.

In the USA health care costs attributable to delirium are upwards of USD164 billion annually, yet there are no established biological markers to guide the diagnosis or management of the condition. Recent studies may now help clinicians assess an individual patient's risk of developing post-operative delirium, enabling preventive measures to safeguard their health.

Scientists at the Beth Israel Deaconess Medical Center (Boston, MA, USA) and their colleagues screened plasma from adults without dementia aged 70 and older undergoing major non-cardiac surgery using data from the Successful Aging after Elective Surgery Study. Of the 566 patients enrolled, 24% experienced delirium. Plasma was collected at four time points: preoperatively (PREOP), in the post anesthesia care unit (PACU), on postoperative day two (POD2) and at the one-month follow-up appointment (PO1MO).

Cases and controls were matched on six variables that may influence the relationship between C-reactive protein (CRP) and postoperative delirium: age within five years; baseline general cognitive performance (GCP) within five points; and an exact match for sex, surgery type, presence of vascular comorbidity, and apolipoprotein E (APOE) ε4 carrier status. For APOE genotyping, DNA was extracted from cellular material collected at PREOP and analyzed.

The initial proteomics phase used isobaric tags for relative and absolute quantitation (iTRAQ) mass spectrometry assay to examine five sets of matched case-control plasma samples across the four time points in the discovery cohort. Mass spectrometry data was obtained using the AB Sciex 4800 MALDI-TOF/TOF instrument (AB Sciex, Framingham, MA, USA). After analyzing five matched pairs using the iTRAQ system, they selected one protein that met two criteria for enzyme-linked immunosorbent assay (ELISA) validation. ELISA plates were read using a Synergy plate reader (BioTek Instruments, Winooski, VT, USA) at Optical Density (OD =450nm).

C-reactive protein emerged from the proteomics analysis as the strongest delirium-related protein. Validation by ELISA confirmed that compared with controls, cases had significantly higher C-reactive protein levels in the discovery, replication, and pooled cohorts at the PREOP median paired difference [MPD] was 1.97 mg/L, 0.29 mg/L, 1.56 mg/L, the PACU MPD was 2.83 mg/L, 2.22 mg/L, 2.53 mg/L) and the POD2 MPD was 71.97 mg/L, 35.18 mg/L,63.76 mg/L time points, but not at one month postoperative.

Towia A. Libermann, PhD, a senior author of the study said, “Our findings demonstrate that, in patients who go on to develop delirium, CRP levels in blood are slightly increased before surgery and further increase after surgery relative to patients who do not develop delirium. We anticipate that the most specific delirium biomarkers will be found at very low concentrations and not among the most common proteins.” The study was published on March 25, 2016, in the journal Biological Psychiatry.

Related Links:
Beth Israel Deaconess Medical Center
AB Sciex
BioTek Instruments
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.